|
|
||||||||


* Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Universidad Autonóma de Madrid, Cantoblanco, Madrid E-28049;
Hospital Ramón y Cajal, Carretera de Colmenar Km 9, Madrid E-28034;
Department of Animal Pathology, Veterinary School, Universidad Complutense de Madrid, Madrid E-28040; and
§ Centro de Biología Molecular/CSIC, Universidad Autónoma de Madrid, Cantoblanco, Madrid E-28049, Spain
1Correspondence: Centro Nacional de Biotecnología, Carretera de Colmenar Km 16, Cantoblanco, Madrid E-28049, Spain. E-mail: acarrera{at}cnb.uam.es
Alterations in the cell division:cell death ratio induce multiple autoimmune and transformation processes. Phosphoinositide 3-kinase (PI3K) controls cell division and cell death in vitro, but its effect on the function of the cellular immune system and on tumor formation in mammals is poorly characterized. Here we show that transgenic mice expressing in T lymphocytes an active form of PI3K derived from a thymic lymphoma, p65PI3K, developed an infiltrating lymphoproliferative disorder and autoimmune renal disease with an increased number of T lymphocytes exhibiting a memory phenotype and reduced apoptosis. This pathology was strikingly similar to that described in mice exhibiting heterozygous loss of the tumor suppressor PTEN, a lipid and protein phosphatase. We show that overexpression of PTEN selectively blocks p65PI3K-induced 3T3 fibroblast transformation. Moreover, the early development of T cell lymphomas in p65PI3K Tg p53-/- mice indicated that PI3K contributes to tumor development. These observations demonstrate that constitutive activation of PI3K extends T cell survival in vivo, affects T cell homeostasis, and contributes to tumor generation, supporting a model in which selective increases in one type of PTEN substrate, the PI3K-derived lipid products, induce tumorigenesis. PI3K thus emerges as a potential target in autoimmune disease and cancer therapy.R.-Borlado, L., Redondo, C., Alvarez, B., Jimenez, C., Criado, L. M., Flores, J., Marcos, M. A. R., Martinez-A., C., Balomenos, D., Carrera, A. C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Key Words: lymphoproliferative disease autoimmunity cancer phosphoinositide 3-kinase PTEN
This article has been cited by other articles:
![]() |
L. Xue, A. Barrow, and R. Pettipher Novel Function of CRTH2 in Preventing Apoptosis of Human Th2 Cells through Activation of the Phosphatidylinositol 3-Kinase Pathway J. Immunol., June 15, 2009; 182(12): 7580 - 7586. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Alcazar, I. Cortes, A. Zaballos, C. Hernandez, D. A. Fruman, D. F. Barber, and A. C. Carrera p85{beta} phosphoinositide 3-kinase regulates CD28 coreceptor function Blood, April 2, 2009; 113(14): 3198 - 3208. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Sela, M. Dayan, R. Hershkoviz, O. Lider, and E. Mozes A Peptide That Ameliorates Lupus Up-Regulates the Diminished Expression of Early Growth Response Factors 2 and 3 J. Immunol., February 1, 2008; 180(3): 1584 - 1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Alcazar, M. Marques, A. Kumar, E. Hirsch, M. Wymann, A. C. Carrera, and D. F. Barber Phosphoinositide 3 kinase {gamma} participates in T cell receptor induced T cell activation J. Exp. Med., November 26, 2007; 204(12): 2977 - 2987. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-P. Liu, Y.-C. Kuo, C.-C. Shen, M.-H. Wu, J.-F. Liao, Y.-L. Lin, C.-F. Chen, and W.-J. Tsai (S)-Armepavine inhibits human peripheral blood mononuclear cell activation by regulating Itk and PLC{gamma} activation in a PI-3K-dependent manner J. Leukoc. Biol., May 1, 2007; 81(5): 1276 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Xie, R. Patel, T. Wu, J. Zhu, T. Henry, M. Bhaskarabhatla, R. Samudrala, K. Tus, Y. Gong, H. Zhou, et al. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr Int. Immunol., April 1, 2007; 19(4): 509 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Deane, M. G. Kharas, J. S. Oak, L. N. Stiles, J. Luo, T. I. Moore, H. Ji, C. Rommel, L. C. Cantley, T. E. Lane, et al. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling Blood, April 1, 2007; 109(7): 2894 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Gustin, C. K. Korgaonkar, R. Pincheira, Q. Li, and D. B. Donner Akt Regulates Basal and Induced Processing of NF-{kappa}B2 (p100) to p52 J. Biol. Chem., June 16, 2006; 281(24): 16473 - 16481. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Barber, A. Bartolome, C. Hernandez, J. M. Flores, C. Fernandez-Arias, L. Rodriguez-Borlado, E. Hirsch, M. Wymann, D. Balomenos, and A. C. Carrera Class IB-Phosphatidylinositol 3-Kinase (PI3K) Deficiency Ameliorates IA-PI3K-Induced Systemic Lupus but Not T Cell Invasion J. Immunol., January 1, 2006; 176(1): 589 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-i. Fukuda, A. Hayashi, A. Utsunomiya, Y. Nukada, R. Fukui, K. Itoh, K. Tezuka, K. Ohashi, K. Mizuno, M. Sakamoto, et al. Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL) PNAS, October 18, 2005; 102(42): 15213 - 15218. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Jones, S. D. Saibil, J. M. Pun, A. R. Elford, M. Bonnard, M. Pellegrini, S. Arya, M. E. Parsons, C. M. Krawczyk, S. Gerondakis, et al. NF-{kappa}B Couples Protein Kinase B/Akt Signaling to Distinct Survival Pathways and the Regulation of Lymphocyte Homeostasis In Vivo J. Immunol., September 15, 2005; 175(6): 3790 - 3799. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Lacalle, C. Gomez-Mouton, D. F. Barber, S. Jimenez-Baranda, E. Mira, C. Martinez-A., A. C. Carrera, and S. Manes PTEN regulates motility but not directionality during leukocyte chemotaxis J. Cell Sci., December 1, 2004; 117(25): 6207 - 6215. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gomez-Mouton, R. A. Lacalle, E. Mira, S. Jimenez-Baranda, D. F. Barber, A. C. Carrera, C. Martinez-A., and S. Manes Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis J. Cell Biol., March 1, 2004; 164(5): 759 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, K. Nakamura, Y. Jiang, H. Tsurui, S. Matsuoka, M. Abe, M. Ohtsuji, H. Nishimura, K. Kato, T. Kawai, et al. Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus Hum. Mol. Genet., January 15, 2004; 13(2): 171 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. C. J. van de Donk, D. Schotte, M. M. J. Kamphuis, A. M. W. van Marion, B. van Kessel, A. C. Bloem, and H. M. Lokhorst Protein Geranylgeranylation Is Critical for the Regulation of Survival and Proliferation of Lymphoma Tumor Cells Clin. Cancer Res., November 15, 2003; 9(15): 5735 - 5748. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Alvarez, E. Garrido, J. A. Garcia-Sanz, and A. C. Carrera Phosphoinositide 3-Kinase Activation Regulates Cell Division Time by Coordinated Control of Cell Mass and Cell Cycle Progression Rate J. Biol. Chem., July 11, 2003; 278(29): 26466 - 26473. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Rodriguez-Borlado, D. F. Barber, C. Hernandez, M. A. Rodriguez-Marcos, A. Sanchez, E. Hirsch, M. Wymann, C. Martinez-A., and A. C. Carrera Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio J. Immunol., May 1, 2003; 170(9): 4475 - 4482. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jimenez, C. Hernandez, B. Pimentel, and A. C. Carrera The p85 Regulatory Subunit Controls Sequential Activation of Phosphoinositide 3-Kinase by Tyr Kinases and Ras J. Biol. Chem., October 25, 2002; 277(44): 41556 - 41562. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shi, C. Xie, D. Kreska, J. A. Richardson, and C. Mohan Genetic Dissection of SLE: SLE1 and FAS Impact Alternate Pathways Leading to Lymphoproliferative Autoimmunity J. Exp. Med., August 5, 2002; 196(3): 281 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Jones, A. R. Elford, M. J. Parsons, L. Wu, C. M. Krawczyk, W.-C. Yeh, R. Hakem, R. Rottapel, J. R. Woodgett, and P. S. Ohashi CD28-dependent Activation of Protein Kinase B/Akt Blocks Fas-mediated Apoptosis by Preventing Death-inducing Signaling Complex Assembly J. Exp. Med., August 5, 2002; 196(3): 335 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro-oncol, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF] |
||||
![]() |
J. A. Fox, K. Ung, S. G. Tanlimco, and F. R. Jirik Disruption of a Single Pten Allele Augments the Chemotactic Response of B Lymphocytes to Stromal Cell-Derived Factor-1 J. Immunol., July 1, 2002; 169(1): 49 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Birle, N. Bottini, S. Williams, H. Huynh, I. deBelle, E. Adamson, and T. Mustelin Negative Feedback Regulation of the Tumor Suppressor PTEN by Phosphoinositide-Induced Serine Phosphorylation J. Immunol., July 1, 2002; 169(1): 286 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma Hematology, January 1, 2002; 2002(1): 241 - 262. [Abstract] [Full Text] |
||||
![]() |
A.-C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes & Dev., April 1, 2001; 15(7): 807 - 826. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |